AstraZeneca's new hypertension drug succeeds in Phase III

2025-07-15 19:21:23

Today, the reporter learned from AstraZeneca that its research drug Baxdrostat achieved the primary and all secondary endpoints in the BaxHTN Phase III clinical trial for patients with uncontrolled or refractory hypertension. According to the positive results of the BaxHTN Phase III trial, compared with placebo, both doses of Baxdrostat (2 mg and 1 mg) showed statistically significant and clinically significant reductions in patients' sitting systolic blood pressure (SBP) at 12 weeks of treatment, and the trial also successfully achieved all secondary endpoints.

AstraZeneca

Email Subscription

Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.

Weekly Highlights

                                    Novo Nordisk (NVO.N): The downward revision of its fiscal year sales forecast is related to declining sales of its weight loss drug Wegovy in the United States.
                            2025-07-29

                                    Toyota Motor Corp. is expected to decide as early as Wednesday evening whether to resume operations at its Japanese factories.
                            2025-07-30

                                    CATL's losses widened in the afternoon, with A shares falling more than 4% to below 280 yuan and H shares falling more than 7%.
                            2025-07-30

                                    BYD: Sales of new energy vehicles in July were 344,296 units. The cumulative sales of new energy vehicles from January to July were 2,490,250 units, a year-on-year increase of 27.35%.
                            2025-08-01

                                    Amazon (AMZN.O) shares plummeted 7.1 percent, wiping out $178 billion in market value.
                            2025-08-01